We are live on ! Find out more
OREX

Orexigen Therapeutics, Inc.
OREX

Delisted

OREX was delisted on the 3rd of April, 2018.

Back to rankings

130 hedge funds and large institutions have $475M invested in Orexigen Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

72% more call options, than puts

Call options by funds: $11.7M | Put options by funds: $6.81M

21% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 39

8% more capital invested

Capital invested by funds: $442M → $475M (+$33.2M)

6% more funds holding

Funds holding: 123 → 130 (+7)

Holders
130
Holders Change
+7
Holders Change %
+5.69%
% of All Funds
4.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
47
Reduced
39
Closed
8
Calls
$11.7M
Puts
$6.81M
Net Calls
+$4.9M
Net Calls Change
+$1.03M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$12.4M
2
NMC
NEA Management Company
Maryland
+$7.82M
3
Deutsche Bank
Deutsche Bank
Germany
+$6.65M
4
State Street
State Street
Massachusetts
+$5.46M
5
BFA
BlackRock Fund Advisors
California
+$3.49M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$7.14M
2
RG
Redmile Group
California
-$6.96M
3
First Manhattan
First Manhattan
New York
-$6.05M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.76M
5
CII
CR Intrinsic Investors
Connecticut
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
26
SAC Capital Advisors
Connecticut
$4.31M +$2.86M +42,250 +151%
TAM
27
Tiverton Asset Management
Delaware
$4.29M – – –
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
$4.16M -$1.34M -19,720 -23%
CII
29
CR Intrinsic Investors
Connecticut
$3.92M -$2.14M -31,537 -33%
MCM
30
Montibus Capital Management
Oregon
$3.82M -$1.32M -19,512 -24%
VAM
31
Visium Asset Management
New York
$3.78M -$7.14M -105,440 -63%
EIM
32
Essex Investment Management
Massachusetts
$3.59M -$190K -2,811 -5%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$3.49M +$534K +7,885 +16%
Citigroup
34
Citigroup
New York
$3.31M -$1M -14,826 -22%
Goldman Sachs
35
Goldman Sachs
New York
$3.26M +$3.05M +45,032 +552%
Allianz Asset Management
36
Allianz Asset Management
Germany
$3.02M -$59.3K -875 -2%
Principal Financial Group
37
Principal Financial Group
Iowa
$2.95M -$213K -3,145 -6%
TCIM
38
TIAA CREF Investment Management
New York
$2.83M -$55.8K -824 -2%
Fidelity International
39
Fidelity International
Bermuda
$2.69M +$2.96M +43,780 New
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$2.62M +$614K +9,068 +27%
DCM
41
Driehaus Capital Management
Illinois
$2.59M +$612K +9,037 +27%
Geode Capital Management
42
Geode Capital Management
Massachusetts
$2.53M +$323K +4,767 +13%
Hudson Bay Capital Management
43
Hudson Bay Capital Management
Connecticut
$2.29M +$829K +12,241 +49%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$2.28M +$252K +3,720 +11%
JP Morgan Chase
45
JP Morgan Chase
New York
$2.27M -$1.92M -28,318 -43%
Millennium Management
46
Millennium Management
New York
$1.87M +$1.92M +28,406 +1,349%
BIM
47
BlackRock Investment Management
Delaware
$1.65M +$129K +1,903 +8%
Invesco
48
Invesco
Georgia
$1.52M +$1.1M +16,314 +193%
ARTA
49
A.R.T. Advisors
New York
$1.3M +$607K +8,956 +73%
Charles Schwab
50
Charles Schwab
California
$1.26M +$128K +1,885 +10%
1
2
3 4 5

OREX Hedge Fund Activity: Q3 2013 in Review

130 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q3 2013, worth a combined $475M — up 7.5% from $442M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new OREX positions and 8 closed out — a net gain of 9 holders — while 47 added to existing stakes and 39 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $12.4M. The largest seller was Visium Asset Management, cutting an estimated $7.14M.

  • 130 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q3 2013, up from 123 in Q2 2013.
  • Funds reported $475M of Orexigen Therapeutics, Inc. stock for Q3 2013, up 7.5% quarter-over-quarter.
  • 17 funds opened new Orexigen Therapeutics, Inc. positions in Q3 2013 and 8 closed out, a net change of +9 holders.
  • The largest Orexigen Therapeutics, Inc. buyer in Q3 2013 was Fidelity Investments, an estimated $12.4M added.
  • The largest Orexigen Therapeutics, Inc. seller in Q3 2013 was Visium Asset Management, an estimated $7.14M sold.

Based on aggregated 13F filings for Q3 2013.